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Abstract
Although ARS-interacting multifunctional protein 2 (AIMP2, also named as MSC p38) was first found as a component for a
macromolecular tRNA synthetase complex, it was recently discovered to dissociate from the complex and work as a potent
tumor suppressor. Upon DNA damage, AIMP2 promotes apoptosis through the protective interaction with p53. However, it
was not demonstrated whether AIMP2 was indeed pathologically linked to human cancer. In this work, we found that a
splicing variant of AIMP2 lacking exon 2 (AIMP2-DX2) is highly expressed by alternative splicing in human lung cancer cells
and patient’s tissues. AIMP2-DX2 compromised pro-apoptotic activity of normal AIMP2 through the competitive binding to
p53. The cells with higher level of AIMP2-DX2 showed higher propensity to form anchorage-independent colonies and
increased resistance to cell death. Mice constitutively expressing this variant showed increased susceptibility to carcinogen-
induced lung tumorigenesis. The expression ratio of AIMP2-DX2 to normal AIMP2 was increased according to lung cancer
stage and showed a positive correlation with the survival of patients. Thus, this work identified an oncogenic splicing variant
of a tumor suppressor, AIMP2/p38, and suggests its potential for anti-cancer target.
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Introduction
Alternative splicing is implicated in the regulation of gene
function and diversification [1–3]. Although this process can
provide another level of flexibility in gene regulation, the
disruption in the balance between splicing variants or the
generation of aberrant alternative splicing variants can lead to
pathological disorder. In this context, the discovery of aberrant
splicing variants that are related to human diseases and the
understanding of their mode of action would provide important
insights into diagnosis and therapy of the related diseases. In this
work, we identified a splicing variant of tumor suppressor, AIMP2,
that is associated with cancer formation and characterized its
working mechanism and pathological implication.
Nine different aminoacyl-tRNA synthetases (ARSs) form a
macromolecular complex with three auxiliary factors, AIMP1, 2,
and 3. Many of the enzyme components were previously shown to
be involved in diverse signaling pathways with their unique
mechanisms [4,5]. The three AIMPs appear to facilitate the
assembly of the whole complex through the interactions with each
other as well as with their specific target enzymes [6]. These
factors also play diverse regulatory roles. AIMP1/p43 is secreted
as a cytokine controlling angiogenesis [7], immune response [8,9],
tissue regeneration [10] and as a hormone for glucose homeostasis
[11]. It is also implicated in the regulation of the autoimmune
phenotype such as lupus [12]. AIMP3/p18 was demonstrated to
be a tumor suppressor responding to DNA damage [13,14] or
oncogenic stimuli [15].
AIMP2 plays a pivotal role in the control of cell fate. It shows
anti-proliferative activity by enhancing the growth-arresting signal
of TGF-b signal [16]. AIMP2 also promotes cell death via the
activation of p53 [17] and apoptotic signal of TNF-a [18]. For this
reason, mice lacking AIMP2 were neo-natal lethal due to lung
failure resulted from overproliferation of lung epithelial cells. In
addition, the AIMP2 heterozygous mice with reduced expression
level of AIMP2 showed a higher susceptibility to tumorigenesis
[19]. Based on these results, AIMP2 is considered as a
haploinsufficient tumor suppressor with unique working mecha-
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nism. Here we identified a splicing variant of AIMP2 that can
compromise the normal function of AIMP2 and induce tumor-
igenesis.
Results
Cancer-associated generation of exon 2–deleted splicing
variant
The gene encoding AIMP2 is located in chromosome 7 and
consists of four exons (Figure 1A). Interestingly, the expressions of
its splicing variant lacking exon 2 (encoding 69aa) was reported in
the EST database for cervical carcinoma (BI259092) and muscle
rhabdomyosarcoma (BI115365). We designated this variant
AIMP2-DX2. To see whether the generation of this variant has
any association with cancer formation, we compared the
expression of AIMP2-full length and –DX2 with normal and lung
cancer cells by RT-PCR. With the primers, JTV-13 and 11
(Figure 1A top and Figure S1), two PCR products were apparently
generated in lung cancer cell lines (Figure 1B top). Isolation and
sequencing of the two products determined that the upper and
lower bands resulted from the full-length (AIMP2-F) and exon 2-
deleted (AIMP2-DX2) transcripts, respectively. RT-PCR with the
primer, DX2-S2, which is specific to the junction of exon 1 and 3,
and JTV5 (Figure 1A and Figure S1) generated the PCR product
of the expected size (27.8kD/756 bp) at higher levels in lung
cancer cell lines compared with normal cells (Figure 1B middle).
To see whether the increased expression of AIMP2-DX2 is also
observed in human cancer tissues, we isolated the cancer regions
from different types of human lung cancer patients and compared
the AIMP2-F and –DX2 by RT-PCR. In many of the clinical
tissues, the AIMP2-DX2 expression was increased in cancerous
regions compared to the normal regions (Figure 1C). To further
evaluate the higher expression of AIMP2-DX2, we compared the
AIMP2-F and –DX2 expressions in adenocarcinoma of human
lung cancer using the poly-A polymerase alpha (POPOLA) gene as
a reference [20] using quantitative RT-PCR. The expression ratio
of AIMP2-DX2 to PAPOLA, was increased to 0.32 in the cancer
region compared to 0.14 in the normal region. In contrast, the
ratio of AIMP2-F expression to PAPOLA was only slightly
increased in cancer region (Figure 1D).
To confirm the identity of the two forms of AIMP2, we
introduced each of pcDNA3.1 plasmid encoding mouse AIMP2-F
or –DX2 into AIMP2-deficient mouse embryonic fibroblasts
(MEFs) and each transfectant was subjected to Western blotting
with AIMP2 antibody, which can recognize both AIMP2-F and
–DX2. When proteins were extracted from the transfectants and
subjected to immunoblotting with the anti-AIMP2 antibody,
AIMP2-F and –DX2-transfected cells showed specific bands at the
location of expected molecular weight while no signal was
Figure 1. Generation of AIMP2 splicing variant lacking exon 2.
(A) The AIMP2/p38 structural gene consists of four exons encoding a
total of 320 aa (NM_006303) with three introns. The 312 aa version of
AIMP2 is also reported as U24169. Both forms appear to work similarly
for most of our experiments although we do not know the reason for
the existence of the two forms at this point. The sequences of exon 1, 2
and 3, and the primers, JTV13, JTV5, JTV11 and DX2-S2 are shown in
Figure S1. (B) Expression of AIMP2-F and –DX2 was examined in
different lung cells (Normal: WI-26, NL-20; tumorigenic: A549, H322,
H460 and H157) by RT-PCR using their specific primers shown above.
The pair of the primers, JTV13 and JTV11, generates the two PCR
products, one from the transcript of AIMP2-full length (upper band) and
the other from the exon 2-lacking transcript (lower band). RT-PCR with
the primers, DX2-S2, (specific to the junction site of exon 1 and 3, Figure
S1) and JTV5, generates the amplicon only from AIMP2-DX2 transcript.
Actin was used as the control. (C) Expression of AIMP2-F and AIMP2-
DX2 was also determined in different types of human lung cancer
tissues and their normal counterparts by RT-PCR. The primer pairs of
JTV-13/JTV-5, and DX2-S2/JTV-5 were used for RT-PCR of AIMP2-F and –
DX2, respectively. (D) The expression of AIMP2-F and –DX2 were
determined in adenocarcinoma (n = 14) and normal (n = 11) lung tissues
by quantitative real-time RT-PCR. The cancer regions were obtained by
laser microdissection system from archival formalin-fixed paraffin-
embedded (FFPE) patient tissues for RT-PCR as described in experi-
mental procedures. PAPOLA [41] was chosen as the endogenous
reference gene for quantitative RT-PCR. The expression results were
analyzed by Mann-Whitney test and statistical analyses were achieved
using SPSS software (SPSS, Chicago, IL). Each dot represents the
expression values of AIMP2-F and -DX2 calibrated to the expression
level of PAPOLA. The mean values are shown as lines. **, P,0.01 (E) The
larger and smaller amplicons that were generated by RT-PCR with the
primers JTV13 and JTV11 were cloned and expressed in AIMP2-deficient
MEFs and their expression was determined by Western blotting with
monoclonal anti-AIMP2 antibody (#324) that recognizes both forms of
AIMP2. Small interference RNAs targeting AIMP2-F and –DX2 were
designed and introduced into A549 cells, and their specific effect on the
expression of the corresponding transcripts was determined by
Western blotting with anti-AIMP2 antibody (right panel).
doi:10.1371/journal.pgen.1001351.g001
Author Summary
Lung cancer is one of the most common cancers and a
leading cause of death resulting from cancer. Despite
intensive investigation, effective therapeutic targets and
reliable biomarkers are still limited. Here we found that a
tumor suppressor, AIMP2 (MSC p38), produces a variant
lacking a part of its structure in cancer tissues. We
designated it AIMP2-DX2. This smaller version of AIMP2
compromises the normal tumor suppressive activity of
AIMP2 and induces tumor formation. We also found that
the expression of AIMP2-DX2 was increased according to
cancer progression. In addition, the patients with higher
expression of AIMP2-DX2 showed lower survival than
those with lower levels of this variant. Suppression of
AIMP2-DX2 slowed tumor growth, suggesting it as a new
therapeutic target. In summary, this work newly identified
a tumor-inducing factor, AIMP2-DX2, that can be used as a
therapeutic target and biomarker associated with lung
cancer.
Oncogenic Variant of Tumor Suppressor AIMP2
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observed from the EV-transfected cells (Figure 1E left). We also
introduced siRNAs designed to specifically target either AIMP2-F
or –DX2 into A549 cells in order to validate the identity of the two
forms. Each siRNA specifically suppressed the expression of
AIMP2-F and –DX2 as expected (Figure 1E right), further
confirming the identity of the two transcripts.
Carcinogen-induced mutation increases AIMP2-DX2 level
To see whether the expression of AIMP2-DX2 can be induced
by carcinogenic stress, we treated the WI-26 normal lung cells with
chemical carcinogen, anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-
epoxide (BPDE), and selected the surviving cells. We then
compared the expression levels of AIMP2-DX2 between the
normal WI-26 and surviving cells by Western blotting. The
surviving cells expressed higher levels of AIMP2-DX2 compared
to that of the normal cells (Figure 2A), suggesting that AIMP2-
DX2 can be induced by carcinogenic stress. To determine
whether the increased expression of AIMP2-DX2 involves any
mutations that might affect alternative splicing pattern between
AIMP2-F and –DX2, we isolated the genomic DNA encoding
AIMP2 from the surviving cells. We determined the DNA
sequences and identified a C39 deletion mutation and a base
substitution of A152 to G in exon 2. Furthermore there were
substitutions of C227 to T and A342 to G in intron 3 (Figure S2).
We then employed the plasmid (pGINT) containing a splicing
cassette that can monitor the alternative splicing by the
expression of GFP in 293 cells [21] (Figure 2B). The 1263 base
genomic fragment spanning intron 1 (630 bp from 39end), exon
2 (207 bp) and intron 2 (426 bp from 59end) of AIMP2 was
inserted into the gene encoding GFP (pGINT-exon 2)
(Figure 2C). If the exon 2 of AIMP2 is included in splicing, it
will be inserted into the middle of GFP, thereby ablating green
fluorescence. If exon 2 is skipped during splicing, the normal
GFP will be expressed and the cells will generate green
fluorescence. To see whether this system would work as
expected, pGINT or pGINT-exon 2 was transfected into 293
cells with pRINT that expresses RFP in the same splicing
cassette as a control. In both transfectants, RFP was expressed
to similar degree, indicating that splicing process occurred
normally. In contrast, the transfectants of pGINT-exon 2
showed significantly reduced green fluorescence compared with
the pGINT transfectants (Figure 2D). This indicates that
splicing process including exon 2 of AIMP2 mainly takes place.
We then introduced pGINT containing the exon 2 insert with
different mutations and determined whether any of these
mutations induced exon 2 deletion during splicing. Among the
transfectants of four tested mutations, the cells containing A152G
substitution expressed GFP to the level similar to pGINT control.
In control, the cells with three other mutations showed the
reduced GFP levels as pGINT-exon 2 wild type (Figure 2E). The
effect of the four mutations on exon 2 splicing was also determined
by RT-PCR of pGINT-exon 2 constructs. Among the four tested
mutant sequences, the DNA containing A152G substitution
induced exon 2 skipping and mainly generated GFP transcript
whereas the three other mutants generated the transcript like the
wild type DNA (Figure 2F).
To identify splicing factors involved in this process, exonic
splicing enhancer (ESE) finder program ver. 3.0 [22,23] was used
for the serine/arginine-rich (SR) protein-binding motif analysis in
exon 2. Motif sequences for the SR proteins, SF2/ASF, SC35,
SRp40 and SRp55, were used for the ESE finding and the
mutation sites located in exon 2, DC39 and A152G, were
predicted to be located in the ESEs for SF2/ASF (Figure S3A).
Since A152G mutation which induced exon 2 skipping was
predicted to severely affect the potential ESE site for SF2/ASF, we
tested the effect of SF2/ASF on the expression level of AIMP2-
DX2. Knockdown of SF2/ASF reduced both AIMP2-F and -DX2
(Figure S3B) and overexpression of SF2/ASF increased the both
forms (Figure S3C), implying that AIMP2 pre-mRNA is a
functional substrate for SF2/ASF-mediated splicing.
To demonstrate the direct interaction between SF2/ASF and
exon 2 RNA, exon 2 RNA was detected after co-precipitation with
SF2/ASF. The association of SF2/ASF was observed with WT
Figure 2. Splicing variant of AIMP2 is increased by carcinogen-
induced mutation. (A) Normal lung WI-26 cells were incubated in the
presence of BPDE for 4 weeks. The surviving colonies were isolated and
further cultivated for additional 2 weeks after removal of BPDE to
establish stable cell lines. The expression of AIMP2-F and –DX2 in each
isolated cell line was determined by Western blotting with anti-AIMP2
antibody. (B) Schematic representation of the EGFP reporter cassette
that monitors alternative splicing in cells (pGINT) [21]. Normal splicing
process would delete the intervening DNA sequence that is inserted
into the open reading frame of EGFP to restore the expression of EGFP.
(C) The intervening sequence is inserted into the 146 base position of
717 bp open reading frame of EGFP. The DNA region spanning the 39
region of intron 1 (630 bp)-exon 2 (207 bp)-intron 2 (426 bp) of AIMP2
was inserted into the open reading frame of EGFP (pGINT-exon 2). If
splicing skips exon 2, EGFP will be expressed (upper). However, the
normal splicing including exon 2 will break the open reading frame of
EGFP (lower). (D) pGINT (left) or pGINT-exon 2 (right) was introduced
into HEK293 cells with pRINT (Red fluorescence protein reporter
cassette that generates RFP through constitutive splicing intron), and
expression of GFP and RFP was observed. (E) pGINT plasmids containing
AIMP2 gene with the indicated mutations were tranfected into HEK293
cells and the expression of EGFP was determined. While pGINT empty
vector generated EGFP, pGINT containing the wild type exon 2 and
flanking intron regions reduced the expression of EGFP. The effect of
the indicated mutations on the exon 2 splicing was monitored by the
production of EGFP. All the transfectants showed similar degree of RFP,
indicating that the difference in EGFP did not result from the variation
of transfection efficiency. (F) Expression of the two transcripts (GFP
transcripts with and without AIMP2 exon 2 insert) was also determined
by RT-PCR.
doi:10.1371/journal.pgen.1001351.g002
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exon 2, but not with A152G exon 2 RNA (Figure S3D). Direct
interaction between SF2/ASF and exon 2 RNA was also tested by
incubating SF2/ASF with exon 2 WT or A15G probe. Among the
two probes, only the WT exon 2 probe strongly bound to SF2/
ASF (Figure S3E). SF2/ASF controls alternative splicing of tumor
suppressors and cell cycle regulatory genes and also shows
abnormal expression in various cancers including lung carcinoma
[24-26]. Although SF2/ASF appears to control the expression of
both AIMP2-F and AIMP2-DX2, the expression of the DX2 form
seems to be more dependent on the levels of SF2/ASF. Thus,
enhanced expression of SF2/ASF would increase the relative ratio
of AIMP2-DX2 to AIMP2-F.
AIMP2-DX2 interferes with pro-apoptotic activity of
AIMP2
We investigated how AIMP2-F (full length) and -DX2 would
affect DNA damage-induced cell death by monitoring the sub-G1
portion of A549 cells. The sub-G1 portion was increased by
adriamycin treatment and it was further augmented by the
introduction of AIMP2-F (Figure 3A). However, the exogenous
addition of AIMP2-DX2 reduced the adriamycin and AIMP2-F-
induced sub-G1 portion of cells (Figure 3A). Since AIMP2-F was
shown to mediate the apoptotic response of p53 to DNA damage,
we monitored how AIMP2-F and –DX2 would affect the
expression of the luciferase reporter gene with the promoter,
Growth Arrest and DNA Damage 45 (GADD45), under the
control of p53. Luciferase activity was increased according to the
added amount of AIMP2-F in the presence of adriamycin
(Figure 3B). However, adriamycin-induced luciferase activity was
decreased by the addition of AIMP2-DX2 in a dose-dependent
manner (Figure 3C).
We also tested the effect of AIMP2-F and –DX2 by fluorescence
staining of the cells. AIMP2-F and –DX2 were transfected into the
immortalized MEF cells as GFP fusion proteins and the cells were
treated with DNA damaging agent, etoposide, for 8 h and the
effects of the two proteins on cell death were monitored by cell
morphology change using bright field and fluorescence microsco-
py. The cells expressing GFP-AIMP2-F showed apoptotic
morphology with high frequency while other cells still maintained
normal shape (Figure 3D). The cells transfected with GFP-AIMP2-
DX2 was observed in 16 h after etoposide treatment. Many cells
turned to apoptotic morphology as shown by light microscopy
whereas most of the GFP-AIMP2-DX2 expressing cells kept
normal morphology (Figure 3E). All of these results further
confirmed pro-apoptotic activity of AIMP2-F and suggested that
AIMP2-DX2 may render resistance to cell death, perhaps by
interfering with the normal activity of AIMP2-F.
AIMP2–DX2 blocks pro-apoptotic interaction of AIMP2-F
with p53
Since AIMP2-F mediates the apoptotic response to DNA
damage via p53, we investigated whether AIMP2-DX2 would
influence the pro-apoptotic interaction of AIMP2-F with p53. To
see this possibility, we first tested whether AIMP2-DX2 could bind
to p53 like AIMP2-F. We transfected the two forms of AIMP2 into
A549 cells. The endogenous p53 was immunoprecipitated and the
co-precipitation of AIMP2-F or –DX2 with p53 was determined
by Western blotting. Both of AIMP2-F and –DX2 were bound to
p53 with a similar affinity (Figure 4A). We then prepared
radioactive AIMP2-F and DX2 by in vitro translation and each
protein was mixed with GST or GST-p53. GST-p53 was
precipitated with glutathione-Sepharose and co-precipitation of
AIMP2-F and –DX2 was determined by autoradiography. Both
proteins were precipitated with GST-p53 but not with GST,
further confirming their ability to bind p53 (Figure 4B).
We then investigated whether AIMP2-DX2 would compete
with AIMP2-F for the interaction with p53 by in vitro pull-down
assay using GST-p53 and radioactively synthesized AIMP2-F or
–DX2. The binding of AIMP2-F to p53 was decreased by the
addition of AIMP2-DX2 in dose-dependent manner (Figure 4C).
Conversely, AIMP2-F decreased the binding of AIMP2-DX2 to
p53 (Figure 4D). These results confirmed that the two forms of
AIMP2 would compete for the binding to p53. Since AIMP2-F
can block the interaction between p53 and MDM2 [17], we
examined how AIMP2-DX2 would affect the interaction between
p53 and MDM2. We added different amounts of AIMP2-F and
–DX2 to the binding mixture of radioactive MDM2 and GST-p53,
and checked how they would influence the association of p53 and
MDM2. While MDM2 binding to p53 was decreased as more
AIMP2-F was added (Figure 4E), the addition of AIMP2-DX2 gave
no inhibitory effect on the p53-MDM2 association (Figure 4F).
These results suggest that AIMP2-DX2 does not block MDM2
binding to p53. We then examined the binding of AIMP2-F and
–DX2 to p53 at endogenous levels. In normal lung WI-26 cells, we
Figure 3. AIMP2-DX2 compromises pro-apoptotic activity of
AIMP2-F. (A) AIMP2-F and –DX2 were transfected into A549 cells and
their effects on adriamycin-induced cell death were compared by sub-
G1 population using flow cytometry. *: P,0.05. **: P,0.01. A549 cells
were transfected with luciferase reporter gene under the control of
GADD45 promoter with the indicated amounts of AIMP2-F (B) or
AIMP2-DX2 (C), and incubated for additional 12 hours. Adriamycin was
treated to the transfectants for 12 hours and luciferase activity was
measured by luminometer. (D) MEF cells were transfected with
pcDNA3.1 vector and selected by G418 for 2 weeks to establish
immortalized cell line. The cells were then transfected with pEGFP-C2
plasmid expressing AIMP2-F. After 24 h, VP-16 (10 mM, Sigma) was
added on the dishes and the cells were cultivated for 8 h and the cell
morphology was monitored by bright field and fluorescence (489 nm
excitation/509 nm emission) microscopy. The images were converged
by Metamorph 7.0 imaging program. Bar, 20 mm. (E) EGFP-fused AIMP2-
DX2 was also expressed in the same cells and cell morphology was
examined in 16 h after VP-16 treatment. Bar, 20 mm.
doi:10.1371/journal.pgen.1001351.g003
Oncogenic Variant of Tumor Suppressor AIMP2
PLoS Genetics | www.plosgenetics.org 4 March 2011 | Volume 7 | Issue 3 | e1001351
observed UV-dependent association of AIMP2-F with p53
(Figure 4G left). However, in lung cancer A549 cells expressing
higher level of AIMP2-DX2, endogenous AIMP2-DX2 bound to
p53 to the extent similar to AIMP2-F, further supporting the
potential competition between the two forms of AIMP2 for the
binding to p53 (Figure 4G right).
We next compared the effect of AIMP2-F and –DX2 on the
cellular stability of p53 after knocking down AIMP2-F and –DX2.
A549 cells were treated with cycloheximide (CHX) to block the de
novo cellular protein synthesis, and AIMP2-F or –DX2 was
specifically suppressed with their specific siRNAs. Then, the cells
were harvested at time intervals and the cellular levels of p53 were
determined by Western blot analysis. When AIMP2-F was
suppressed, the cellular level of p53 was more rapidly reduced
compared with that of the si-control-treated cells. In contrast, the
level of p53 was maintained for longer duration in the cells in
which AIMP2-DX2 was suppressed with its specific siRNA
(Figure 4H). This property means that AIMP2-DX2 would work
like a dominant negative mutant against the pro-apoptotic
interaction of AIMP2-F with p53. For this reason, cells showed
an increased sensitivity to etoposide-induced cell death when
endogenous AIMP2-DX2 was suppressed, (Figure S4A), and this
increased sensitivity was abrogated in p53-deficient cells (Figure
S4B), indicating that the effect of AIMP2-DX2 involves p53.
AIMP2-DX2 stays as free form
Although AIMP2-DX2 expression can be induced, the total
amount of AIMP2-DX2 appears to be much lower than that of
AIMP2-F in most of the cell lines. This observation poses the
question whether AIMP2-DX2 could effectively compete with
AIMP2-F for the binding to p53. In this regard, it should be noted
that AIMP2-F is mainly anchored to the multisynthetase complex
in cytosol [6]. In other words, only a portion of AIMP2-F is
recruited to p53 upon DNA damage while the majority of AIMP2-
F is still bound to the complex [17]. We checked whether AIMP2-
DX2 would also bind to the multi-synthetase complex like AIMP2-
F by yeast two hybrid assay. KRS (lysyl-tRNA synthetase), one of
the components for the multisynthetase complex, was used as the
testing pair for AIMP2-F and –DX2 because AIMP2 make a
strong binding to KRS [6,27]. Although AIMP2-DX2 showed the
binding ability to p53 with a similar affinity to AIMP2-F, it lost the
normal affinity to KRS as determined by yeast two hybrid assay
(Figure 5A). This result was further confirmed by co-immunopre-
cipitation assay. When Myc-AIMP2-F or –DX2 was immunopre-
cipitated in 293 cells, KRS was co-precipitated with AIMP2-F, but
not with –DX2 (Figure 5B). Conversely, when KRS was
immunoprecipitated, co-precipitation of AIMP2–DX2 was signif-
icantly lower than that of AIMP2-F (Figure 5C).
We also compared the cellular levels of AIMP2-F and –DX2 that
exist unbound to the multisynthetase complex. This time, we used
AIMP1, another component of the complex [28], instead of KRS, for
immunoprecipitation to make sure that we are not looking at only the
binary interaction between AIMP2 and KRS. AIMP1 was
immunoprecipitated with its specific antibody, and the co-precipita-
tion of AIMP2-F and -DX2 was determined. AIMP2-F, but not
AIMP2-DX2, was co-precipitated with AIMP1 (Figure 5D left). We
then examined the amounts of AIMP2-F and –DX2 left in the
immune-depleted supernatant. The majority of the cellular AIMP2-
DX2 was detected in the supernatant that was comparable to the free
form of AIMP2-F (Figure 5D right). All of these results suggest that
AIMP2-DX2 would exist mainly as free form, not bound to the
multisynthetase complex, whereas AIMP2-F is bound to the complex.
Thus, AIMP2-DX2 would be able to compete with AIMP2-F that is
dissociated from the multisynthetase complex for the binding to p53
and Far-upstream element-binding protein (FBP) although the total
amount of AIMP2-DX2 is lower than AIMP2-F (Figure 5E).
Tumorigenic property of AIMP2-DX2
Since AIMP2 works as a potent tumor suppressor, AIMP2-DX2
may exert the opposite activity by interfering with the normal
Figure 4. The effect of AIMP2-DX2 on the interaction of AIMP2-F
with p53. (A) p53 was immunoprecipitated from A549 cells transfected
with Myc-AIMP2-F and –DX2, and co-precipitation of the two AIMP2
proteins with p53 was determined with anti-Myc antibody. (B) AIMP2-F
and –DX2 were radioactively synthesized by in vitro translation and each
protein (20 ml of the in vitro translation reaction) was mixed with GST or
GST-p53. GST proteins were precipitated with glutathione-Sepharose
beads and co-precipitation of AIMP2-F and –DX2 was determined by
autoradiography. (C) Radioactively synthesized AIMP2-F and –DX2 as
above were used to see whether the two proteins would compete for the
interaction with p53. The indicated amount of AIMP2-DX2 (indicated by
microliter volume) was mixed with the fixed amount of AIMP2-F and GST-
p53 to see the effect of AIMP2-DX2 on the AIMP2-F binding to p53. (D)
Conversely, the indicated amount of AIMP2-F was added to the fixed
amount of AIMP2-DX2. (E) MDM2, AIMP2-F and –DX2 were radioactively
synthesized as above and the indicated volumes (ml) of AIMP2-F was
added to the binding mixture of MDM2 and GST-p53. The mixture was
precipitated with glutathione-Sepharose and co-precipitation of MDM2
and AIMP2-F was determined by autoradiography. (F) The same
experiment as above was conducted except that AIMP2-DX2 was added
at the indicated amounts to the mixture. (G) WI-26 and A549 cells were
subjected to UV irradiation and lysed. The extracted proteins were
immunoprecipitated with anti-p53 antibody (FL-393), separated by SDS-
PAGE and immunoblotted by immunoblotting with the anti-AIMP2
antibody. (H) A549 cells were treated with cycloheximide (CHX) to block
de novo protein synthesis. AIMP2-F and –DX2 were suppressed with their
specific siRNAs and the cellular levels of p53 were monitored by Western
blotting at indicated time interval.
doi:10.1371/journal.pgen.1001351.g004
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activity of AIMP2. To determine this possibility, we isolated WI-
26 cells, in which AIMP2-DX2 expression was induced by BPDE
to different degrees, and compared their propensity to anchorage-
independent colony formation. The same number of the cells was
spread on agar plates and the resulting numbers of colonies were
counted. The number of the anchorage-independent colonies
showed a positive correlation to the expression levels of AIMP2-
DX2 (Figure 6A), implicating the potential oncogenic property of
AIMP2-DX2. To further confirm these results, we transfected an
empty vector, AIMP2-F and AIMP2-DX2 into MEF, and then
performed anchorage-independent colony forming assay. Trans-
fection of AIMP2-F and –DX2 resulted in fewer and more
colonies compared to that of empty vector (Figure 6B).
To see whether an increased expression of AIMP2-DX2 may
render susceptibility to tumorigenesis, we generated transgenic
mice in which AIMP2-DX2 is constitutively expressed, as
described in Materials and Methods. The increased expression
of AIMP2-DX2 was confirmed by Southern blotting with the
primers specific to the junction of exon 1 and 3, and by RT-PCR
with the primers specific to CMV transgenic vector (Figure S5). In
addition, we compared the expression of AIMP2-DX2 by Western
Figure 5. Differential interaction of AIMP2-F and –DX2 with the
multisynthetase complex. (A) The interaction of AIMP2-F and –DX2
with the multi-synthetase complex was determined by yeast two hybrid
assay using KRS as the target protein. p53 was used as a positive control
and the positive interaction was indicated by the blue colony formation
on X-gal-containing yeast medium. (B) The interaction of AIMP2-F and –
DX2 with KRS was tested by co-immunoprecipitation assay. Myc-AIMP2-
F or –DX2 was expressed in 293 cells and immunoprecipitated with
anti-Myc antibody. Co-precipitation of KRS was determined with anti-
KRS antibody. (C) KRS was immunoprecipitated with its specific
antibody and co-precipitation of Myc-AIMP2-F, and –DX2 was
determined with anti-Myc antibody. Expression of KRS and Myc-tagged
AIMP2 were determined by Western blotting with anti-KRS and -Myc
antibodies in the whole cell lysates (WCL), respectively. (D) Protein
lysates of A549 cells were immunoprecipitated with anti-AIMP1
antibody, and co-precipitation of AIMP2-F and –DX2 was determined
by Western blotting with anti-AIMP2 antibody (left). The immune-
depleted supernatants were then subjected to Western blotting with
anti-AIMP1 and –AIMP2 antibodies (right). (E) Schematic representation
for the working mode of AIMP2-F and –DX2 in p53-mediated apoptosis.
Upon DNA damage, AIMP2 in the multisynthetase complex is activated
and binds to p53 to protect it from MDM2-mediated degradation.
AIMP2-DX2 does not associate with the complex and exists as free form.
AIMP2-DX2 competes with AIMP2-F for the binding to p53 and
compromises pro-apoptotic activity of AIMP2-F via p53.
doi:10.1371/journal.pgen.1001351.g005
Figure 6. Oncogenic property of AIMP2-DX2. (A) BPDE-trans-
formed WI-26 cells with different expression ratio of AIMP2-DX2 to
AIMP2-F were tested for their propensity to anchorage-independent
colony formation. The relationship between the ratio of AIMP2-DX2 to
AIMP2-F and the average numbers of the produced colonies with
standard deviation in each colony were displayed as dot plot. (B) WI-26
cells stably expressing EV, AIMP2-F and -DX2 were also compared for
anchorage-independent colony formation. The same numbers of the
three cell lines (200 cells per plate) were spread on the testing medium
and the resulting colonies were counted and shown as bar graph. The
experiments were repeated three times. (C) Two independent 12.5d
MEFs were obtained from the wild type and AIMP2-DX2 transgenic
mice and compared for the expression levels of p53 and phosphory-
lation status of p53. Expression of AIMP2-DX2 was also determined by
Western blot analysis. Tubulin was used as a loading control. 12.5d
MEFs isolated from the wild type and AIMP2-DX2 transgenic mice were
treated with adriamycin (1 mM) for 24 h and the sub-G1 populations
induced by adriamycin treatment were determined by flow cytometry
(D). The cell growth in completed media was also monitored (E).
Susceptibility to benzopyrene-induced lung carcinogenesis was com-
pared between the wild type and AIMP2-DX2 transgenic mice by tumor
incidence (F) and area (G). The area was represented by the numbers
given in Bio-Image J 2.0. (H) Three lungs were isolated from the wild
type and AIMP2-DX2 transgenic mice and subjected to hematoxylin and
eosin staining.
doi:10.1371/journal.pgen.1001351.g006
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blotting and found that AIMP2-DX2 is highly expressed in the
transgenic mice (Figure S5). We isolated MEFs from the wild type
and AIMP2-DX2 transgenic mice and compared the cellular
levels of p53 and its phosphorylation. The p53 level and
phosphorylation were significantly reduced in the transgenic mice
(Figure 6C). Normal and AIMP2-DX2 MEFs were also treated
with adriamycin and their sensitivity to cell death was compared
by flow cytometry. AIMP2-DX2 transgenic cells showed lower cell
death (Figure 6D), resulting in the enhanced cell number
(Figure 6E) compared to the wild type cells. The wild type
(n = 14) and AIMP2-DX2 transgenic mice (n = 18) were also
compared for their susceptibility to benzo[a]pyrene-induced lung
carcinogenesis. Lungs were isolated and the formation of lung
cancers were determined as described previously [19] and tumor
area was analyzed by Bio-Image J 2.0. The AIMP2-DX2
transgenic mice showed a significant increase in tumor incidence
and regions compared to the wild type counterpart (Figure 6F, 6G
and 6H). All of these results suggest the oncogenic potential of
AIMP2-DX2.
Suppression of AIMP2-DX2 reduces tumor growth
To see whether we can control tumor progression by
suppressing the expression of AIMP2-DX2, we established a lung
cancer xenograft model with the lung cancer cell line, H460. We
introduced siRNA against AIMP2-DX2 and siRNA control via
intratumoral injection four times at three day interval from 5 days
after cell transplantation. The tumor growth was retarded by the
injection of si-DX2 (Figure 7A). We isolated the tumors and
compared the expression levels of p53. The tissues isolated from
the si-DX2-injected tumors showed higher expression of p53
(Figure 7B), indicating that the si-DX2-injected tumors may have
enhanced cell death through the activation of p53. We also
determined whether intratumoral injection of si-DX2 actually
reduced the expression level of AIMP2-DX2 in tumor region by
quantitative real-time PCR. The cellular levels of AIMP2-DX2
were reduced about 50% by the introduction of si-DX2 compared
to those in the siRNA control-injected tumors (Figure 7C). For an
additional experiment, we introduced luciferase-expressing A549
lung cancer cells into the mice via tail vein. After 2 months of
cancer cell inoculation, siRNA control and si-DX2 were delivered
to the lungs via intubation four times in three day interval and the
mice were incubated another 2 weeks. The lung cancer cell growth
was monitored by the luciferase activity released from the growing
cancer cells. While the control siRNA-injected mice (n = 5) showed
a 2.4 to 4.8 fold increase in luciferase activity, si-DX2-delivered
mice showed 1.1 to 2.8 fold increase or even a shrinkage of tumors
(Figure 7D). We also isolated the lungs and compared the tumor
area by histological analysis. Compared to the siRNA control-
delivered tumors, si-DX2-delivered tumors showed smaller cancer
regions (Figure 7E). Specific suppression of AIMP2-DX2 tran-
script was also confirmed by quantitative RT-PCR (Figure S6).
Next, we monitored the effect of AIMP2-DX2 suppression on
tumor growth using a carcinogen-induced lung cancer model.
Lung cancer in mice was induced by the injection of benzo[a]-
pyrene (B[a]P). Then, we prepared the plasmid DNA encoding
shRNA targeted against AIMP2-DX2, and delivered it into lungs
via inhalation device eight times in three day interval (Figure S7).
We isolated the lungs from the EV- and sh-DX2 treated mice and
compared the tumor growth by H&E staining. The DX2-shRNA
treated lungs contained smaller tumor area compared to those
treated with an empty vector (Figure 7F, 7G and Figure S8). To
assure that the plasmid is efficiently delivered to various lung
tissues, the same plasmid encoding GFP was prepared and
delivered to lung using the same method. The lungs were isolated
from the treated mice and the delivery of the plasmid was
monitored by the expression of GFP (Figure S8A and S8B).
Delivery of sh-DX2 from the treated lungs was confirmed by PCR
(Figure S8C). All of these results consistently demonstrated that
suppression of AIMP2-DX2 expression can retard tumor growth.
Figure 7. Knock-down of AIMP2-DX2 can retard tumor growth.
(A) NCI-H460 (16107) cells were injected at both flanks of 6 week old
BALB/c nude mice. When volume of tumor mass reached to 250 mm3,
anti-DX2 or control siRNAs were intratumorally injected at 50 mg/kg
dosage once in three days for four times (n = 7 per each group). The
tumor volumes were determined as described in Materials and
Methods. (B) Tumors isolated from anti-DX2 and control siRNA treated
mice were subjected to immunohistochemistry with the antibodies
against p53 (C) Cellular levels of AIMP2-F and –DX2 transcripts in the
tissues of the isolated tumors were compared by quantitative RT-PCR.
(D) Luciferase-expressing A549 lung cancer cells (16107) were injected
into tail vein of BALB/c nude mice and the dissemination of the cells
into lungs was monitored by IVIS (Xenogen). Each group of the injected
mice (n = 5/group) intratracheally received si-scramble (50 mg) or si-
AIMP2-DX2 (50 mg) mixed with GDM-PEI in 50 ml of 0.9% saline. The
tumor growth was monitored by photon flux released from luciferin as
described in Materials and Methods. The data were expressed as
photon-flux (photons/s/cm2/steradian). The photon flux for each
measurement is represented by color scale. (E) Tumor tissues isolated
from each group were examined by hetatoxylin and eosin staining. Two
examples from each group are displayed. (F) The plasmid DNA
encoding shRNA against AIMP2-DX2 was mixed with glucosylated
polyethyleneimine (G-PEI), vaporized in humid vacuum chamber and
inhaled for 30 minutes through the nose of the mice that contained
benzopyrene-induced lung cancers as described in Materials and
Methods. The mice were randomly sacrificed at time interval and the
tumor growth was determined by the area of tumor tissues in the total
measured area (n = 4). (G) Histological analysis of tumor regions by
hematoxylin and eosin staining. Arrow heads indicate tumor nodules.
doi:10.1371/journal.pgen.1001351.g007
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Correlation of AIMP2-DX2 expression with cancer stage
and patient survival
Since AIMP2-DX2 compromises tumor suppressive activity of
AIMP2-F via competitive inhibition, the expression ratio of
AIMP2-DX2 to AIMP2-F may have a relationship to cancer
progression. To explore this possibility, we obtained squamous cell
carcinoma and adenocarcinoma tissues from lung cancer patients
who were in different stages, and the expression ratios of AIMP2-
DX2 to -F were compared. The AIMP2-DX2/F ratios were
gradually increased from those of the normal tissues according to
cancer stage (Figure 8A).
We also determined the expression of AIMP2-DX2 and
AIMP2-F in the normal and cancerous regions isolated from 97
NSCLC patients by quantitative RT-PCR. The patients were
divided into two groups based on the expression ratios of AIMP2-
DX2 to AIMP2-F. 43 patients showed higher expression ratios of
AIMP2-DX2 to AIMP2-F in cancerous regions compared with
those in the normal regions while the other 54 patients did not
show apparent difference between the cancer and normal tissues.
The patient group with tumors that expressed higher ratios of
AIMP2-DX2 to AIMP2-F exhibited a poorer overall (Figure 8B)
and disease-free survival (Figure 8C) pattern compared to the
group in which the patients did not show higher expression of
AIMP2-DX2 although the degree of difference between the two
groups varied to some extent. When we examined the prognostic
values with several factors, the AIMP2-DX2 to AIMP2-F
expression ratio showed the most significant correlation with
patient survival (Table 1, Table S1, Hazard Ratio for Overall
Survival = 6.83, P = 0.045; Hazard Ratio for Disease Free
Survival = 2.25, P = 0.046). Altogether, the results further support
that increased expression of AIMP2-DX2 may reflect the
aggressiveness of cancer cells.
Discussion
Although alternative splicing can be a way for the diversification
of a gene function [1–3], the generation of inappropriate splicing
product can be pathologic. In particular, the cancer-associated
formation of alternative splicing variants has been reported in
prostate cancer [29]. Oncogenic alternative splicing variants of
Acute Myeloid Leukemia 1 (AML1) and TrkA have been found in
ovarian cancer [30] and neuroblastoma [31], respectively.
Similarly, the splicing variant of p53 was also shown to modulate
the normal activity of p53 [32,33]. In p63, another p53 family
tumor suppressor, a splicing variant expressed dominant negative
activity [34–36]. Based on these findings, alternative splicing
variants with oncogenic properties are expected to be found in
other tumor suppressors. Here we report a generation of an
oncogenic alternative splicing variant of tumor suppressor AIMP2
in lung cancer cells and patient tissues (Figure 1).
The base substitution of A152 to G was found at the exon 2
region of AIMP2 in carcinogen-induced transformed cells. This
mutation induced exon 2 skipping, resulting in the increase of
AIMP2-DX2 production (Figure 2E and 2F). These results further
support the association of AIMP2-DX2 with tumorigenesis.
Generation of AIMP2-DX2 does not seem to seriously affect the
cellular level of AIMP2-F transcript. Perhaps this is because the
amount of AIMP2-DX2 is minor compared to that of AIMP2-F or
because the loss of AIMP2-F resulting from the generation of
AIMP2-DX2 is re-filled by a compensatory expression. Further
detailed investigation is needed to see how alternative splicing
between AIMP2-F and –DX2 is regulated.
AIMP2-DX2 competes with AIMP2-F for the binding to p53
(Figure 4). In our previous work, deletion mapping determined
that the C-terminal region (161–312 aa) of AIMP2 binds to the N-
Figure 8. Correlation of expression ratio of AIMP2-DX2 to
AIMP2-F with lung cancer stage and survival. (A) AIMP2-DX2/F
ratios of patient tissues with cancer stage IA (n = 5), IB (n = 6) and
IIB,IIIB (n = 7) were compared with that of normal lung tissues (n = 5)
by quantitative RT-PCR method as described. The ratios were increased
significantly (p,0.05) according to tumor progression. Cancer stages
were classified based on TNM (tumor, nodes, metastasis) system.
Kaplan-Meier estimates of the (B) OS and (C) DFS according to the level
of the expression ratios of AIMP2-DX2 to AIMP2-F in 97 lung cancer
patients. The OS was significantly worse in patients with higher
expression ratio of AIMP2-DX2 to AIMP2-F than in patients with lower
expression ratio. P- values were calculated by the log-rank test.
doi:10.1371/journal.pgen.1001351.g008
Table 1. Multivariate analysis for overall and disease-free
survival by demographics, smoking status, histological type,
and pathologic stage.
Overall Survival Disease-Free Survival
Variables HR (95% CI) P HR (95% CI) P
Age
(.63/#63 years)
13.7 (1.36–90.9) 0.03 3.59 (1.42–9.01) 0.01
Gender
(Female/Male)
0.91 (0.06–13.9) 0.95 1.04 (0.29–3.68) 0.96
Smoking status
(Ever/Never)
0.87(0.10–7.54) 0.90 0.83 (0.23–2.93) 0.77
Histology
(AD/SQ)
1.98 (0.35–11.2) 0.44 2.38 (0.76–7.40) 0.13
Stage
(II-IIIA/I)
1.40 (0.26–7.57) 0.69 2.60 (1.03–6.57) 0.04
Adjuvant treatment
(No/Yes)
2.54 (0.41–15.1) 0.32 1.39 (0.51–3.86) 0.52
DX2 expression
(High/Low)
6.83 (1.05–44.5) 0.045 2.55 (1.01–6.42) 0.046
Row percentage shown. HRs, 95% CIs and their corresponding P-values were
calculated using multivariate Cox proportional hazard models, adjusted for age,
gender, smoking status, tumor histology, pathologic stage and adjuvant
treatment. P-values were statistically significant after Bonferroni correction for
multiple testing.
doi:10.1371/journal.pgen.1001351.t001
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terminal region of p53 [17]. Thus, it is not surprising that AIMP2-
DX2 retains its binding ability to p53 because the exon 2 encodes
the region of 46–113 aa of AIMP2, which is not involved in the
interaction with p53. Based on the conformational modeling, the
exon 2 domain is expected to protrude outward and may give a
steric hindrance for MDM2 to bind p53 (data not shown). Since
AIMP2-DX2 polypeptide is smaller than AIMP2-F and may not
have the expected protuberance of exon 2, it may not be able to
block the MDM2 binding to p53.
AIMP2 also plays critical roles in the apoptotic activity of TNF-
a [18] and the anti-proliferative activity of TGF-b [16]. Although
in this study we focused on the antagonistic function of AIMP2-
DX2 against the pro-apoptotic activity of AIMP2-F via p53 in
response to DNA damage, it may also influence the normal
activity of AIMP2 in these two other pathways with a similar mode
of action, namely, through the competitive binding to the target
proteins. Since AIMP2-F augments TGF-b-dependent growth
arrest via downregulation of FBP and c-Myc [16], we examined
whether AIMP2-DX2 would also work against AIMP2-F in this
pathway. While overexpression of AIMP2-F increased p53 level, it
reduced the levels of FBP and c-Myc (Figure S9A). Exogenous
supplementation of AIMP2-DX2 reversed these effects of AIMP2-
F (Figure S9A). We also examined the effect of AIMP2-DX2 on
the ubiquitination of AIMP2-F target proteins. While p53
ubiquitination was inhibited by AIMP2-F, it was interfered by
the addition of AIMP2-DX2 (Figure S9B). Conversely, ubiquitina-
tion of FBP was enhanced by the addition of AIMP2-F (Figure
S9C) and this effect was inhibited by exogenous introduction of
AIMP2-DX2 (Figure S9C). We also compared the expression level
of c-Myc as well as p53 among WI-26 and other lung cancer cell
lines such as H460, H1975 and H292 (all of these cell lines contain
wild type p53) in which AIMP2-DX2 levels are increased. In these
cell lines, c-Myc level was more increased compared to that of the
normal WI-26 cells while p53 levels were more decreased (Figure
S9D). Interestingly, all of these cells lines showed increased SF2/
ASF levels, further supporting the regulatory connection between
this splicing factor and expression of AIMP2-DX2. Based on these
results, AIMP2-DX2 is expected to compromise not only the pro-
apoptotic activity but also anti-proliferative activities of AIMP2-F.
Considering the functional importance of AIMP2 in cell fate
determination as well as in the assembly of multisynthetase
complex [37,38], its cellular level and activity may need to be
tightly controlled. For this, expression of AIMP2-DX2 can be a
part of a normal regulatory mechanism to finely control the
function of AIMP2. Perhaps, the generation of AIMP2-DX2 could
become out of control by mutations that can disrupt the normal
splicing process and lead to cancer formation. The responsible
mutations can be located in trans-acting splicing factors or in the
promoter or gene encoding AIMP2. Suppression of AIMP2-DX2
in lung cancer reduced tumor growth in lung cancer model
(Figure 7), and lung cancer patient analysis demonstrated the
correlation of AIMP2-DX2 expression with cancer progression
and patient survival (Figure 8). Combined with the molecular
working mechanism and cellular effect, AIMP2-DX2 appears to
be a novel therapeutic target against lung cancer. It would be
interesting to see whether this variant would be also involved in
other types of cancer.
Materials and Methods
Cell culture and reagents
Normal lung cell line, WI-26, was purchased from Korea Cell
Line Bank (KCLB) and NL-20 was provided by Dr. M.-H. Cho
(Seoul National University). Lung carcinoma cell lines A549 and
NCI-H460 were obtained from ATCC, and H322 and H157 from
KCLB. The siRNAs targeting AIMP2-F and -DX2 were designed
as the sequences of AGAGCUUGCAGAG ACAGGUUAGACU
and UCAGCGCCCCGUAAUCCUGCACG UG, respectively.
AIMP2-DX2 polypeptide was used as the antigen and the selected
hybridoma clone (#324) generated the monoclonal antibody
recognizing both of AIMP2-F and –DX2. This antibody was used
for immunoblotting and immunohistochemistry. Anti-KRS and
–AIMP1 antibodies were purchased from Abchem.
Quantitative RT–PCR
The expression of AIMP2-DX2 and –F were analyzed by
quantitative real time RT-PCR. Eleven normal lung samples and
fourteen patients with lung adenocarcinoma were retrospectively
identified from the surgical pathology files of the Department of
Pathology at Samsung Medical Center and their archival
formalin-fixed paraffin-embedded (FFPE) tissues were obtained.
All the samples were collected anonymously according to
Institutional Review Board guidelines. All patients had undergone
a surgical operation and had received neither chemotherapy nor
radiotherapy before surgical resection. For total RNA extraction
from FFPE tissues, each tissue section was stained with
hematoxylin and cancer regions were microdissected using laser
microdissection system (ION LMD, JungWoo International,
Korea). Paradise Whole Transcript RT Reagent System (Arcturus,
CA, USA) was used for RNA isolation and RT of FFPE samples.
Due to the limitation of RNA amount extracted from FFPE
tissues, half RNA and cDNA were used for reverse transcription
and quantitative RT-PCR, respectively. PCR primers and Taq-
man probes for this study are provided from Metabion (Germany).
Flow cytometry
Cells transfected with the plasmid encoding AIMP2-F or –DX2
were cultivated in the absence or presence of adriamycin, fixed
with 70% ethanol for 1 hour at 4uC and washed with ice-cold PBS
two times. Then, the 16106 cells were stained with PI (50 mg/ml)
containing 0.1% sodium citrate, 0.3% NP40 and 50 mg/ml RNase
A for 40 minutes, and subjected to flow cytometry (FACS Caliber,
Beckton-Dickinson) for the determination of apoptotic cells by
counting sub-G1 cells. For each sample, 20,000 cells were
analyzed using Cell Quest Pro software. All of the experiments
were repeated three times and averaged.
Anchorage-independent colony forming assay
pCDNA3 encoding AIMP2-F and -DX2 were transfected into
12.5 days mouse embryonic fibroblasts. The cell lines stably
expressing each of the transfected plasmid were established by
G418 selection. For soft agar colony assays, the cells were diluted
into 0.3% agar in DMEM containing 10% FBS and seeded in
triplicate onto 0.6% agar containing culture medium. 200 cells
were seeded on each well in 12-well plate. The colonies were fed in
every 3 to 4 days and evaluated after 5 weeks. To evaluate the
correlation between the expression level of AIMP2-DX2 and
colony formation, WI-26 cells (Korean Cell Line Bank) were
treated with 0.1 mM BPDE once in every three days for 4 weeks
and the surviving colonies were observed after 2 weeks from the
chemical treatment. The 20 separate colonies were randomly
selected to establish the cell lines.
Binding assay
For immunoprecipitation, AIMP2-F or DX2 was ectopically
expressed in HEK293 cells by transfection. The cells were lysed
with the lysis buffer containing 1% NP-40, 0.5% deoxycholate and
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protease inhibitor cocktail (Calbiochem). The lysates were
incubated with the antibody against p53 (DO-1, Santacruz), and
precipitated by protein G (Invitrogen) 4uC overnight and co-
precipitation of the two proteins were blotted with anti-Myc or
anti-AIMP2 antibody. For in vitro pull down assay, GST-p53 or
GST was mixed the protein extracts with glutathione-Sepharose in
the PBS buffer containing 1% Triton X-100 and 0.5% N-
laurylsarcosine at 4uC for 2 hours. We synthesized MDM2 and
AIMP2-F or -DX2 by in vitro translation in the presence of [35S]
methionine using TNT Quick coupled Transcription/Translation
system (Promega). The synthesized peptide was added to the GST
protein mixtures above, incubated at 4uC for 4 hours with rotation
in the PBS buffer containing 1% Triton X-100, 0.5% N-
laurylsarcosine, 1 mM DTT, 2 mM EDTA and 300 mM phenyl-
methylsulfonyl fluoride (PMSF), and washed six times with the
same buffer containing 0.5% Triton X-100. We then eluted the
proteins bound to Sepharose beads with the SDS sample buffer,
separated by SDS-PAGE and autoradiographed. For yeast two
hybridization assay, the cDNAs encoding human AIMP2-F, –
DX2, p53 and KRS were obtained by PCR using specific primers.
The PCR products were digested with EcoRI and XhoI, and ligated
into the same sites of pEG202 (LexA) and pJG4-5 (B42). The
interactions between LexA-AIMP2 fragments and B42-KRS or –
p53 were analyzed for their ability to form blue colonies on yeast
medium containing X-gal.
Reporter gene assay
To test the p53-dependent transcriptional activity, the target
gene GADD45-luciferase vector was transfected into A549 cells.
The cells lysates were prepared and reacted by luciferase assay kit
following the manufactuerer’s protocol (Promega) and the
luciferase activity was analyzed using luminometer.
Mutation analysis for AIMP2-DX2 generation
The 1263 bp genomic DNA of AIMP2 covering exon 2 with
flanking introns was amplified with Platinum Taq DNA polymer-
ase high fidelity (Invitrogen) and DNA template from BPDE-
transformed WI-26 cells (WI-26T) with the primers 59GAA-
GAGTCTAACCTGTC TCTGCAAGCTCTTGAG39 and
59AACATGCTCTTGGCT CTGCCTTTG39. The resulting
PCR products were cloned into pGEMT-Easy vector (Promega)
and sequenced. To verify the effect of mutations in WI-26T cells
on AIMP2-DX2 generation, the splicing reporters, pGINT and
pRINT, which express EGFP and RFP, respectively as an
indication of splicing, were kindly provided by Dr. Garcia-Blanco
[21]. The genomic wild type AIMP2 exon 2 regions including cis-
acting splicing elements were amplified with Platinum Taq DNA
Polymerase High Fidelity (Invitrogen) using primers (59GCGC-
GGATCCTCCCAAAGTGCTGGGATTACAGGT39 and 59GC-
GCGTCGACAACATGCTCTTGGCTCTGCCTTTG39) and
WI-26 genomic DNA template, and cloned into pGINT after
BamHI and SalI restriction enzyme digestion. The constructed
plasmid pGINT-exon 2 which contains wild type AIMP2 exon 2
with the flanking intron regions was used as a template for site-
directed mutagenesis to introduce each of the mutations identified
from the WI-26T cells. To assess the effect of mutations on the
generation of AIMP2-DX2, 0.5 mg of pGINT-EX2 wild type and
its mutant derivatives were transfected into HEK293 cells seeded
on a 6-well plate using GenePORTER reagent (Gelantis). The
same amount of pRINT was transfected as a splicing and
transfection control. After 24 hours incubation, the cells were
visualized under fluorescent microscope to detect green and red
fluorescence. The same set of transfected cells were used for RNA
extraction using RNA extraction kit (Qiagen) and cDNA synthesis.
Primer pairs, 59ACGTAAACGGCCACAAGTTC39 and 59AA-
GTCGTGCTGCTTCATGTG 39, were used for the detection of
EGFP or exon 2-included EGFP transcripts.
Sequence analysis for exonic splicing enhancer (ESE)
motifs
Wild type sequence of AIMP2 exon 2 from WI-26 and the exon
2 sequence with mutations found from WI-26T were analyzed for
exonic splicing enhancer (ESE) of four serine/arginine-rich (SR)
proteins. ESE finder program ver. 3.0 was used for the prediction.
The highest sequence score for each SR protein was calculated in
a random-sequence pool and the threshold values were set as the
median of the highest score. The threshold values were as follows:
SF2/ASF heptamer motif, 1.956; SF2/ASF (IgM-BRCA1)
heptamer motif, 1.867; SC35 octamer motif, 2.383; SRp40
heptamer motif, 2.670; and SRp55 hexamer motif, 2.676.
RNA immunoprecipitation assay
HEK293T cells were transfected with GFP-tagged SF/ASF as
well as pGINT-exon 2 or pGINT-exon 2 with A152G mutation
(pGINT-A152G). After 24 h incubation, nuclear fraction was
obtained and subjected to immunoprecipitation using anti-GFP
antibody. GFP-SF2/ASF-bound mRNAs were purified using
Trizol reagent according to the manufacturer’s guideline. Reverse
transcriptase PCR was conducted using AIMP2 exon 2-specific
primers. To verify the effect of A152G mutation on the interaction
with SF2/ASF in vitro, RNA probes encompassing full sequence of
AIMP2 exon 2 were synthesized by in vitro transcription using
[a-32P]UTP and T7 promoter-containing DNA templates ob-
tained from PCR amplification of pGINT-exon 2 WT and
A152G. The RNA probes were incubated at 30uC for 30 min with
GFP-SF2/ASF which was immunoprecipitated as mentioned
above. After washing 3 times with the reaction buffer (20 mM
HEPES, pH 7.8, 200 mM KCl, 20 mM NaCl, 10% glycerol,
2 mM DTT, and 2 mM MgCl2) containing 0.05% NP-40, the
RNA-protein complex was eluted using formaldehyde sample
buffer, separated by electrophoresis in 7.5% urea polyacrylamide
gel, and detected by autoradiography.
Generation of transgenic mice constitutively expressing
AIMP2-DX2
Murine AIMP2/p38 sequence (BC026972) lacking exon 2 was
cloned into pCDNA3.1(+) (Invitrogen) at HindIII and XhoI. The
region of CMV promoter to poly A site was linearized and injected
into mouse fertilized egg of C57BL/6 strain. The insertion of
AIMP2-DX2 was confirmed by Southern blot and PCR analyses
using the genomic DNA isolated from MEF cells. AIMP2-DX2
expression was determined by Northern and Western blot analyses
(see Figure S3 for details).
Non-invasive imaging of cancer growth using
bioluminescence
A549 cells expressing luciferase reporter (107) were injected into
tail veins of five-week-old female BALB/c nu/nu mice. After 5–6
weeks, the dissemination of the cells was monitored by IVIS
(Xenogen). Mice were divided into two group (n = 5/group)
depending on their releasing photon flux and the mixtures of si-
scramble AIMP2-DX2 (50 mg) or si-AIMP2-DX2 (50 mg) with
GDM-PEI (glycerol dimethacrylate polyethyleneimine) [39] in
50 ml of 0.9% saline were delivered intratracheally into lung. To
monitor photon flux, mice were anesthetized with isoflurane
inhalation, and 100 ul of D-luciferin (7.5 mg/ml, Xenogen) were
intraperitoneally (i.p.) injected. Bioluminescence imaging with
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CCD camera (IVIS, Xenogen) was initiated 30 min after injection
for 1–60 seconds, depending on the amount of luciferase activity.
The data were expressed as photon-flux (photons/s/cm2/
steradian).
Intratumoral injection of siRNA
For xenograft experiment, NCI-H460 lung cancer cells (107)
were suspended in 200 ml of 0.9% saline and subcutaneously
injected into 6 weeks old female nude mice. The tumor volumes
were monitored three times a week. 50 mg of siRNA mixed with
GDM-PEI were directly injected into tumors in three directions
for four times in the indicated interval from the point that tumor
volume reached 250 mm3. The volume was calculated by (length x
width x height)/2.
Gene delivery by intranasal inhalation
We designed shRNA against AIMP2-DX2 (TCGAGCGGGC-
CACGTGCAGGACTA TTCAAGAGATAGTCCTGCACGT-
GGCCCGCTTTT, underlined regions are matched to the DX2
sequence) and cloned into IMT-700 vector system (Imgenex) using
SalI and XbaI. The plasmid was mixed with glucosylated
polyethyleneimine (G-PEI) at 1.64:1 weight ratio. After 1 week
from last chemical injection, the DNA mixture was delivered into
lung through intranasal pathway using the humid vacuum
chamber in which the DNA mixture was vaporized. The DNA
vapor was inhaled for 30 minutes through the nose of the mice
that were fixed in the cylinder using Bio-Rad compressor as
previously described [40]. From 6 weeks after the last injection of
BP, the administration of DNA was conducted twice a week for 4
weeks and the tumor areas were measured.
Analysis of AIMP2-DX2 expression in lung cancer patients
To determine expression ratios of AIMP2-DX2 to AIMP2-F in
different lung cancer stages, cDNAs from the frozen tissues of 23
patients with squamous cell carcinoma and adenocarcinoma were
provided from Roswell Cancer Park Institute and analyzed by
real-time PCR as described above. The research subject was
reviewed and determined to be non-human subject research
(NHSR) by the committee for Research Subject Protection of the
Institute. Correlation of AIMP2-DX2 expression with patient
survival was also investigated. This study included patients (n = 97)
with pathological stages I, II or IIIA NSCLC patients who
underwent curative surgical resection at the Kyungpook National
University Hospital (Daegu, Korea) between January 2001 and
December 2008. Patients who underwent chemotherapy or
radiotherapy prior to surgery were excluded to avoid the effects
on DNA. All the tissues were obtained at the time of surgery and
then rapidly frozen in liquid nitrogen and stored at -80uC until the
relevant bioassays were conducted. The histologic types of lung
cancers, according to the World Health Organization classifica-
tions, were as follows: 44 cases (45.4%) of squamous cell
carcinomas and 53 cases (54.6%) of adenocarcinomas. The
pathologic staging of the tumors, which was determined according
to the standard of the American Joint Committee on Cancer
(AJCC), was as follows: 59 patients (60.8%) of stage I, 20 patients
(21.6%) of stage II and 18 patients (18.6%) of stage IIIA. Written
informed consent was obtained from all patients prior to surgery
and this study was approved by the Institutional Review Board of
the Kyungpook National University Hospital. Overall survival
(OS) was measured from the day of surgery until the date of death
or to the date of the last follow-up. Disease-free survival (DFS) was
calculated from the day of surgery until recurrence or death from
any cause. The survival estimates were calculated using the
Kaplan-Meier method. The differences in OS or DFS across
different genotypes were compared using the log-rank test. Hazard
ratios (HRs) and 95% confidence intervals (CIs) were estimated
using multivariate Cox proportional hazards models, with
adjustment for age (#63 versus .63 years), gender (male versus
female), smoking status (never- versus ever-smoker), and patho-
logic stage (I versus II-IIIA). All analyses were performed using
Statistical Analysis System for Windows, version 9.1 (SAS
Institute, Cary, NC, USA).
Ethics statement
All human subject researches were approved by the appropriate
ethics committees according to the Declaration of Helsinki. The
correlation of AIMP2-DX2 expression with patient survival rate
was studied under the review of institutional board in Kyungpook
National University Hospital. The title was ‘Identification of
Cancer Specific Biomarker in Lung Cancer: 74005-263’. Roswell
Park Cancer Institute approved the project ‘Evaluation of AIMP2-
DX2 as a Cellular marker for Diagnosis of Lung Cancer:
NHR0020089 through their ethics committee.
Supporting Information
Figure S1 Sequences of AIMP2 exons and PCR primers. The
primer DX2-S2 contains 14 bases of the 39 end of exon 1 and 6
bases of the 59 end of exon 3. The primer binding sites are
indicated in red letters.
Found at: doi:10.1371/journal.pgen.1001351.s001 (0.12 MB TIF)
Figure S2 The mutations induced by BPDE treatment of WI-26
cells and their locations in exon 2 and intron 2 of AIMP2 gene.
The first base of exon 2 was counted as position 1.
Found at: doi:10.1371/journal.pgen.1001351.s002 (0.02 MB TIF)
Figure S3 Trans-acting splicing factor, SF2/ASF, and cis-acting
exon 2 mutations are involved in exon 2 skipping. (A) High score
SR protein motifs in AIMP2 exon 2. The sequences of AIMP2
exon 2 in WI-26 as well as those with mutations found in WI-26T
were analyzed to detect the ESE of four SR proteins using ESE
Finder program ver. 3.0. Motif scores reflect the extent of
matching to a degenerate consensus, and only the scores above the
threshold for each SR protein are shown. Locations of point
mutation found in WI-26T are indicated by asterisks. Deletion of
C39 which is located in the ESE site of SF2/ASF (pink, left panel)
increased the possibility of new ESE sites of SF2/ASF (red, right
panel), SC35 (blue, right panel) and SRp40 (green, right panel)
instead of losing original SF2/ASF site. A152G mutation,
however, made all the ESE scores of its own sequence below
threshold, as shown in SF2/ASF (red and pink, left panel) and
SRp55 (yellow, left panel) sites. ESE of SF2/ASF is mostly affected
by the A152G mutation in that three bars for ESE of SF2/ASF are
disappeared (right panel). The width of each bar, length of the
motif; the placement of each bar along the x axis, the position of a
motif along the exon DNA sequence; and the height of the bar, the
numerical score in the y axis. (B and C) Effects of SF2/ASF on the
cellular levels of AIMP2-F and -DX2. (B) SF2/ASF was knocked
down in H460 cells using specific si-RNA and the two protein
levels were monitored by immunoblotting. (C) GFP-SF2/ASF was
transfected in H460 cells and its effect on the levels of AIMP2-F
and -DX2 was monitored as above. (D and E) A152G mutation in
AIMP2 exon 2 reduced binding affinity of AIMP2 exon 2 to SF2/
ASF. (D) mRNAs bound to immunoprecipitated GFP-SF2/ASF
were purified and detected by RT-PCR using exon 2-specific
primers. Exon 2 sequences were only amplified only in the samples
from HEK 293T cells transfected with both GFP-SF2/ASF and
pGINT-exon 2. No band was detected from the cells where GFP-
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SF2/ASF and pGINT-A152G were expressed together. (E) Full-
length AIMP2 exon 2 sequences with or without A152G mutation
were radioactively synthesized as RNA probes and incubated with
immunoprecipitated GFP-SF2/ASF in vitro. WT probe associated
with SF2/ASF emanating strong signal while RNA probe with
A152G mutation did not.
Found at: doi:10.1371/journal.pgen.1001351.s003 (0.56 MB TIF)
Figure S4 Etoposide-induced cell death is increased by knock-
down of AIMP2-DX2 in p53-dependent manner. (A) After
transfection with si-AIMP2-DX2, same number of cells was
seeded and treated with etoposide. Cell viability was measured by
MTT assay. (B) After transfection with si-AIMP2-DX2 in
HCT116 p53+/- or p53-/- cells, same number of cells was seeded
and treated with etoposide. Cell viability was measured by MTT
assay.
Found at: doi:10.1371/journal.pgen.1001351.s004 (0.14 MB TIF)
Figure S5 Genomic incorporation of AIMP2-DX2-encoding
cDNA was confirmed by Southern blotting (upper panel).
Genomic DNA from AIMP2-DX2 transgenic mice was digested
by Hind III, and the resulting DNA fragments were separated by
agarose gel electrophoresis and then transferred to hi-bond
membrane (Amersham). After baking for 2 hours at 80uC, the
membrane was processed as described in Brightstar Biodetect
nonisotopic detection kit (Ambion). Probe conjugated with biotin
was synthesized as suggested in BrightStar Psoralen-biotin
nonisotopic labeling kit. Briefly, probe was produced by PCR
using primer 59AGGTAAAGCCCTATCATGGAGGCA39 and
59ACAGAGAGAACAG GAAACGTGCGA39 specific to mouse
AIMP2 gene (BC026972). For additional confirmation, we
performed PCR by primer sequences on CMV vector promoter
and AIMP2-DX2 structural gene. The sequences of forward and
reverse primers are 59 CGC TAT TAC CAT GGT GAT GCG 39
and 59 CGA ATG TGT GTG CAC AGT GGA 39, respectively
(middle panel). The expression of AIMP2-F and –DX2 were also
determined by Western blot analysis (lower panel).
Found at: doi:10.1371/journal.pgen.1001351.s005 (0.12 MB TIF)
Figure S6 The effect of si-DX2 on the expression level of
AIMP2-F and –DX2. The expression levels of AIMP2-F and –
DX2 were quantified by quantitative realtime PCR as described in
Materials and Methods.
Found at: doi:10.1371/journal.pgen.1001351.s006 (0.03 MB TIF)
Figure S7 The effect of sh-DX2 on the expression level of
AIMP2-F and –DX2. The mRNAs were prepared from paraffin
embedded lung tissues and the transcript levels of AIMP2-F and –
DX2 were determined by semi-quantitative RT-PCR and gel
electrophoresis.
Found at: doi:10.1371/journal.pgen.1001351.s007 (0.06 MB TIF)
Figure S8 Delivery of GFP-expressing plasmid to the various
parts of mouse lung via intranasal inhalation. (A) GFP-encoding
plasmid was delivered into mouse lung via intranasal inhalation as
described. After 2 days, the mice were sacrificed and various
regions of the lungs were fixed by paraffin block. The plasmid
delivery was then monitored by fluorescence. About 50% of the
examined lung area was evaluated as GFP positive. (B) The GFP-
encoding plasmid delivery was also confirmed by green fluores-
cence in alveoli structure. (C) The delivery of the sh-DX2
encoding plasmid DNA was also confirmed by PCR. The lungs
were isolated after intranasal delivery of the plasmid and the
presence of the plasmid was confirmed by PCR. Left lane indicates
the PCR product of the purified sh-AIMP2-DX2 encoding
plasmid with the specific primers. Middle and right lanes indicate
the PCR product of the DNAs isolated from the lungs isolated
from the mice that received sh-AIMP2-DX2 plasmid and EV via
intranasal inhalation, respectively. The PCR product with the
primers specific to the AIMP2 promoter sequence of the
endogenous genomic DNA was used as the control for PCR.
Found at: doi:10.1371/journal.pgen.1001351.s008 (1.37 MB TIF)
Figure S9 AIMP2-DX2 suppressed the effects of AIMP-F on
p53 and FBP/c-myc. (A) A549 cells were transfected with myc-
tagged AIMP2-F and -DX2. Cells were lysed and subjected to
SDS-PAGE, followed by immunoblotting with anti-p53, anti-FBP,
and anti-c-Myc antibodies. (B) A549 cells were transfected with
myc-tagged AIMP2-F, -DX2 and HA-Ub. P53 was immnopreci-
pitated with anti-p53 antibody (FL-393) and then immunoprecip-
itates were subjected to SDS-PAGE and immunoblotting with
anti-HA antibody. (C) A549 cells were transfected with myc-
tagged AIMP2-F, -DX2 and HA-Ub. FBP was immnoprecipitated
with anti-FBP and then immunoprecipitates were subjected to
SDS-PAGE and immunoblotting with anti-HA antibody. (D) Cells
(WI-26, H460, H1975 and H292) were lysed and the proteins
were separated by SDS-PAGE, followed by immunoblotting with
anti-AIMP2-F, -DX2, anti-p53, anti-SF2/ASF, and anti-c-Myc
antibodies.
Found at: doi:10.1371/journal.pgen.1001351.s009 (1.14 MB TIF)
Table S1 Multivariate analysis for overall survival and disease
free survival by demographics, smoking status, histological type,
and pathologic stage.
Found at: doi:10.1371/journal.pgen.1001351.s010 (0.05 MB TIF)
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